Trial Profile
A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PaZ02
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 31 Aug 2016, according to United Kingdom Clinical Research Network record
- 28 Jan 2016 Accural to date is 82% according to United Kingdom Clinical Research Network